Merck Signs Licensing Agreements with Indian Drugmakers for HIV Pill Alimatravir
Pharma major Merck has signed non-exclusive voluntary licensing agreements with four Indian drugmakers: Aurobindo Pharma, Cipla, Emcure, and Viatris. These agreements will enable the supply of its investigational, once-monthly oral HIV pill, Alimatravir, in 129 low- and middle-income countries (LMICs). The royalty-free agreements aim to expand access to the drug in regions that account for a substantial majority of new HIV diagnoses globally. This initiative is expected to significantly improve the availability and affordability of the treatment in these high-need areas.
Key Points
- Merck signed non-exclusive voluntary licensing agreements with four Indian drugmakers for its HIV pill, Alimatravir.
- The Indian drugmakers involved are Aurobindo Pharma, Cipla, Emcure, and Viatris.
- The agreements are royalty-free and aim to supply the once-monthly oral HIV pill in 129 low- and middle-income countries.
- This initiative is expected to enhance access and affordability of the HIV treatment in regions with a high burden of new HIV diagnoses.
Exam Facts
- Merck signed agreements with Aurobindo Pharma, Cipla, Emcure, and Viatris.
- The drug is Alimatravir, an investigational, once-monthly oral HIV pill.
- The supply will cover 129 low- and middle-income countries (LMICs).
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.